Since the introduction of omalizumab as the first anti-IgE biologic, a new era of targeted CSU therapies has begun, including agents modulating interleukin (IL)-4/IL-13, KIT, and Brutons tyrosine kinase pathways [12]
SS-31 shows promise in the treatment of many neurodegenerative and cognitive disorders such as amyotrophic lateral sclerosis (ALS), Alzheimers, Friedreich ataxia, and glaucoma
Quick Summary If youre short on time, heres what you need to know
The NLM adds that generally, the following criteria describe a candidate for GLP-1 medication therapy: Individuals diagnosed with type 2 diabetes who require additional glycemic control
Several large RCTs have shown that liraglutide and semaglutide are significantly more effective than controls in reducing liver fat content or resolving NASH [20-22]
Endocrinologists: Specialists in hormonal and metabolic disorders, including diabetes and obesity